Successful treatment of cabozantinib-induced pyoderma gangrenosum with ixekizumab therapy: A case report

Dermatol Ther. 2022 Sep;35(9):e15716. doi: 10.1111/dth.15716. Epub 2022 Jul 22.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Anilides / adverse effects
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Humans
  • Pyoderma Gangrenosum* / chemically induced
  • Pyoderma Gangrenosum* / diagnosis
  • Pyoderma Gangrenosum* / drug therapy
  • Pyridines

Substances

  • Anilides
  • Antibodies, Monoclonal, Humanized
  • Pyridines
  • cabozantinib
  • ixekizumab